AtriCure,
Inc. ATRC today announced that it has
entered into a definitive merger agreement under which AtriCure has
agreed to acquire nContact, Inc., a privately held developer of
innovative cardiac ablation solutions.
The transaction consideration consists of an upfront payment of
approximately 3.7 million shares of AtriCure common stock, valued at
$24.60 per share, and approximately $8 million in cash, subject to
closing adjustments. The transaction also includes up to $50 million in
additional contingent consideration based on completion of enrollment of
the CONVERGE IDE trial and PMA approval. Additionally, nContact
shareholders
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in